Annexon (ANNX) Accumulated Depreciation (2019 - 2026)
Annexon (ANNX) posted quarterly Accumulated Depreciation of $9.9 million for Q1 2026, up 28.1% year-over-year from $7.7 million in Q1 2025, and up 5.77% quarter-over-quarter from $9.3 million in Q4 2025.
Annexon (ANNX) Accumulated Depreciation (2019 - 2026) Analysis & Trends
Annexon's Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $9.9 million for Q1 2026.
- In Q1 2026, Accumulated Depreciation rose 28.1% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $9.9 million (up 28.1% YoY), while the FY2025 annual figure was $9.3 million, up 30.17% from the prior year.
- Accumulated Depreciation for Q1 2026 stood at $9.9 million, up from $9.3 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $9.9 million in Q1 2026, with the low at $1.3 million in Q1 2022.
- The 5-year median for Accumulated Depreciation is $5.6 million (2024), against an average of $5.6 million.
- Peak annual rise in Accumulated Depreciation reached 265.4% in 2022, while the deepest fall reached 34.77% in 2022.
- Annexon's Accumulated Depreciation stood at $2.9 million in 2022, then soared by 74.44% to $5.0 million in 2023, then jumped by 42.75% to $7.2 million in 2024, then soared by 30.17% to $9.3 million in 2025, then increased by 5.77% to $9.9 million in 2026.
- Business Quant data shows ANNX's Accumulated Depreciation at $9.9 million in Q1 2026, $9.3 million in Q4 2025, and $8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.42 Mn |
| Mar 31, 2026 | 9.88 Mn |
| Dec 31, 2025 | 9.35 Mn |
| Sep 30, 2025 | 8.80 Mn |
| Jun 30, 2025 | 8.26 Mn |
| Mar 31, 2025 | 7.72 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 6.64 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 5.57 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 3.96 Mn |
| Mar 31, 2023 | 3.42 Mn |
| Dec 31, 2022 | 2.88 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 1.83 Mn |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 789,000.00 |
| Sep 30, 2021 | 3.61 Mn |